Laura Girardi: Medical Inpatients’ Thromboprophylaxis – Was It All Already Said?
Laura Girardi, Clinical and Research Thrombosis Fellow at The Ottawa Hospital, reposted from JAMA Network Open on LinkedIn:
”Medical inpatients’ thromboprophylaxis: was it all already said?
Probably not!
If interested in the topic, you can have a look at the latest SRNMA just published on JAMA Network Open.
Truly honored to have been part of this incredible team led by colleagues Marti C and Blondon Marc (with Marc Righini, Grégoire Le Gal, Helia Robert-Ebadi, Combescure C, Jean-Luc Reny).
Thank you all!”
Quoting JAMA Network Open‘s post:
”Patients hospitalized for acute medical illness who received low-molecular-weight heparin had lower risk of clinically relevant VTE and major bleeding compared with direct oral anticoagulants or unfractionated heparin.”
Title: Pharmacologic Thromboprophylaxis in Medical Inpatients. A Systematic Review and Network Meta-Analysis
Authors: Christophe Marti, Marc Righini, Grégoire Le Gal, Laura Girardi, Helia Robert-Ebadi, Christophe Combescure, Jean-Luc Reny, Marc Blondon

Stay updated on all scientific advances with Hemostasis Today.
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:18Thomas Dayspring: Prognostic Impact of Lp(a) Changes Following Statin Therapy in Patients with CAD
-
Aug 26, 2026, 14:17Khurram Nasir: Are We Debating the Wrong Thing About Research in Medical Training?
-
Aug 26, 2026, 14:15Nathan Connell: Why Format Free Publishing Still Demands Formatting?
-
Aug 26, 2026, 14:14Reza Shojaei: China’s Reliance on Imported Albumin Raises Global Plasma Security Concerns
-
Aug 26, 2026, 14:03Ahmad Masri: The Amyloid Depleter Revolution in ATTR-CM